⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CHRS News
Coherus Oncology, Inc. Common Stock
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
globenewswire.com
ONCY
ALLO
CHRS
PYXS
ELVN
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
CHRS
SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer
globenewswire.com
CHRS
Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)
globenewswire.com
CHRS
Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma
globenewswire.com
CHRS
A 1,000-Year-Old Gospel Likely Written by Women to be Auctioned December 10
accessnewswire.com
CHRS
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
globenewswire.com
CHRS
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
globenewswire.com
CHRS
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
globenewswire.com
CHRS
Coherus Oncology to Report Third Quarter 2025 Financial Results on November 6, 2025
globenewswire.com
CHRS